In short. Small samples, self-report by people who know what they are using, short follow-up, and outcomes chosen after the data. What a readable trial would need instead.
Key points
- Participants randomised, a sham device used so nobody knows their group, a visible outcome agreed in advance and assessed by someone blinded to the allocation, follow-up of months rather than weeks, and a published report whatever the result.
- That combination is achievable, and it is rare here.
Studies of home devices exist, and they are cited constantly. The problem with them is not usually fraud. It is design, and they repeat so consistently that a reader who knows the four can tell what a study supports before reaching its conclusion.
Nobody is blinded
A device is obvious. A participant knows whether they are holding an active device or nothing, and the outcomes usually include how their skin looks to them. That is a self-report from someone who knows what they are using and expects a result. A sham device solves this and is rare in the literature, so most of what is cited rests on the participants’ own impressions of a change they were told to expect.
Short follow-up and the wrong endpoint
Sessions are measured in weeks, and skin changes over months. The measurement is more often an instrument reading than a visible outcome, and a reading is chosen because it is cheap and produces a number that can be analysed. A reading is not meaningless, but it becomes misleading when presented as the outcome it stands in for. Few of these studies follow people long enough for the answer to be worth having.
What a readable trial would look like
Participants randomised, a sham device used so nobody knows their group, a visible outcome agreed in advance and assessed by someone blinded to the allocation, follow-up of months rather than weeks, and a published report whatever the result. That combination is achievable, and it is rare here.
Who paid, and why it matters
Much of the literature is funded by the companies selling the device. That does not make a finding false, and it does decide which questions were asked. A manufacturer has no reason to fund the trial whose endpoint is a visible change after a year, and every reason to fund one that measures a device reading after a few weeks. The published record then looks like evidence for the claim, because the studies that could contradict it were never run.
Outcome switching, and how to spot it
A study intends to measure one thing, finds that something else moved, and reports the second as its result. It is hard to detect from a summary. The safeguard is a protocol stating the outcome in advance, and in this literature that is uncommon, so a reader has to ask which outcome the authors set out to test before deciding what a positive result means.
Three questions that usually end the discussion
- What was measured, and would a person notice it in a mirror?
- Over how long, in how many people, and who assessed the result?
- Who paid for the study, and was there a comparison group at all?
It means a claim repeated confidently in an advertisement is usually standing on work that was never designed to test it, and a reader who asks those three questions can find that out in a few minutes.
Frequently asked questions
Does manufacturer funding make a study false?
No. A manufacturer-run study can be honest, and the design features that make one hard to read appear in independently run work as well. The funding matters because it decides which questions get asked and which of them get published. A company that sells a device is unlikely to fund the trial whose endpoint is a visible change after a year.
Why is a device reading easier to report than a visible result?
Because it produces a number that can be analysed cheaply and consistently. Visible change needs trained assessors, standardised photography or participant report, and all three are slower and easier to influence. An instrument reading is not wrong. It becomes misleading when it is presented as the outcome it was chosen to stand in for.
Can a home device study ever be blinded?
Partly, and a sham device is the usual answer: an identical-looking device that emits nothing meaningful. Where one is used, participants do not know which group they are in, and the result becomes far more informative. Sham devices are uncommon here, which is why so much of the literature rests on participants reporting the change they expected to see.
Risks & Limitations
- No home device can be promised to change your skin, and the claims made for the category are usually broader than the evidence behind them.
- Irritation and pigment change are the commonest problems reported with home use, and they follow more sessions rather than fewer.
- A device used on skin that has not been examined can treat a lesion that needed a diagnosis instead.
- A home device used alongside a clinic course or an active topical can add to an effect that neither the clinic nor the leaflet planned.
When to Seek Care
- A burn that blisters, or swelling of the face or throat, needs urgent care.
- A blister, broken skin or a burn after a home session that is not settling.
- Pigment that has darkened, lightened or spread in the treated area since the sessions began.
- A mole, patch or lesion that is changing, bleeding or not healing, whether or not a device has been used on it.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.